The FDA approval of our disposable ureteroscope validates the device's safety, efficacy, and adherence to rigorous quality standards. This recognition affirms that healthcare professionals can rely on our product for accurate diagnosis and effective treatment of urinary system conditions. By eliminating the need for reprocessing, our disposable ureteroscope reduces the risk of cross-contamination and contributes to enhanced patient safety.
As we celebrate this milestone, we are excited about the opportunities this FDA certification brings as it means our product has been granted access to the market for over 400,000 ureteroscopy examinations conducted annually in the United States. It reinforces our position as a reliable provider of high-quality medical solutions and opens doors to new markets and collaborations. Martin Zhang, the General Manager of MacroLux, stated, "The FDA approval signifies an upgrade to our international business and serves as a testament to the growth of our team." We remain dedicated to driving advancements in minimally invasive procedures and delivering innovative devices that transform patient care.
Single-use for better doctors and patients' experience
Our disposable ureteroscope offers several advantages. Its unmatched slimness can reduce patient discomfort, and its advanced imaging capabilities provide healthcare professionals with a clear visualization of the urinary system, leading to more precise diagnoses and targeted treatments. Furthermore, its disposable design streamlines workflow efficiency, reduces costs associated with reprocessing and enhances overall procedural efficiency.
ABOUT US
MacroLux is a company dedicated to endoscopic diagnosis and treatment, focused on providing innovative and reliable medical solutions to healthcare professionals around the world. We are focusing on the endoscopic intervention therapy market and prioritize the development of single-use electronic endoscope products.